Primary Amyloidosis Clinical Trials

⁃ Subjects are eligible to be included in the study if all the following criteria apply:

• Adult, age 20 and greater

• Subject is clinically stable without cardiovascular-related hospitalizations within 2 weeks prior to enrollment as assessed by the investigators

• Subject is able to provide written informed consent and is willing and able to complete study procedures

• Subject must meet criteria for either ATTR cardiac amyloidosis or AL cardiac amyloidosis from review of medical records as specified below:

• a. ATTR cardiac amyloidosis based on meeting all the following criteria:

• i. Diagnosis of amyloidosis within ten years prior to study screening

• ii. Transthyretin amyloid deposits in cardiac tissue OR Technetium (99mTc) bone scintigraphy with grade 2 or 3 cardiac uptake OR Transthyretin amyloid deposits in non-cardiac tissue with echocardiographic evidence of cardiac involvement or an end-diastolic mean wall thickness \> 12 mm OR Transthyretin amyloid deposits in non-cardiac tissue with cardiac MRI diagnostic of amyloidosis OR Clinical diagnosis of cardiac amyloidosis by the clinical provider

• b. AL cardiac amyloidosis based on meeting all the following criteria:

• i. Diagnosis of amyloidosis within ten years prior to study screening

• ii. Histopathologic diagnosis of amyloidosis with AL protein identification

• iii. Cardiac involvement as defined by: Amyloid deposits in cardiac deposits OR Echocardiography with an end-diastolic mean wall thickness \> 12 mm in the absence of other causes OR Elevated NT-proBNP (\>332 ng/L) in the absence of renal failure or atrial fibrillation OR Cardiac MRI diagnostic of amyloidosis OR Clinical diagnosis of cardiac amyloidosis by the clinical provider